WallStSmart

Merck & Company Inc (MRK)vsTrane Technologies plc (TT)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 204% more annual revenue ($65.77B vs $21.60B). MRK leads profitability with a 13.6% profit margin vs 13.4%. TT appears more attractively valued with a PEG of 2.39. MRK earns a higher WallStSmart Score of 53/100 (C-).

MRK

Buy

53

out of 100

Grade: C-

Growth: 3.3Profit: 8.5Value: 2.7Quality: 4.8
Piotroski: 2/9

TT

Buy

52

out of 100

Grade: C-

Growth: 5.3Profit: 8.0Value: 4.3Quality: 5.5
Piotroski: 6/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MRKSignificantly Overvalued (-15.7%)

Margin of Safety

-15.7%

Fair Value

$97.76

Current Price

$113.56

$15.80 premium

UndervaluedFair: $97.76Overvalued

Intrinsic value data unavailable for TT.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MRK4 strengths · Avg: 9.5/10
Market CapQuality
$277.02B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
36.9%10/10

Every $100 of equity generates 37 in profit

Operating MarginProfitability
38.1%10/10

Strong operational efficiency at 38.1%

Free Cash FlowQuality
$2.93B8/10

Generating 2.9B in free cash flow

TT2 strengths · Avg: 9.5/10
Return on EquityProfitability
36.6%10/10

Every $100 of equity generates 37 in profit

Market CapQuality
$107.57B9/10

Large-cap with strong market position

Areas to Watch

MRK4 concerns · Avg: 3.3/10
P/E RatioValuation
31.5x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
4.9%4/10

4.9% revenue growth

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

PEG RatioValuation
3.432/10

Expensive relative to growth rate

TT4 concerns · Avg: 3.5/10
PEG RatioValuation
2.394/10

Expensive relative to growth rate

P/E RatioValuation
37.2x4/10

Premium valuation, high expectations priced in

Price/BookValuation
12.6x4/10

Trading at 12.6x book value

EPS GrowthGrowth
-2.1%2/10

Earnings declined 2.1%

Comparative Analysis Report

WallStSmart Research

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Return on Equity, Operating Margin.

Bull Case : TT

The strongest argument for TT centers on Return on Equity, Market Cap.

Bear Case : MRK

The primary concerns for MRK are P/E Ratio, Revenue Growth, Piotroski F-Score.

Bear Case : TT

The primary concerns for TT are PEG Ratio, P/E Ratio, Price/Book.

Key Dynamics to Monitor

TT carries more volatility with a beta of 1.21 — expect wider price swings.

TT is growing revenue faster at 6.0% — sustainability is the question.

MRK generates stronger free cash flow (2.9B), providing more financial flexibility.

Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.

Bottom Line

MRK scores higher overall (53/100 vs 52/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Trane Technologies plc

INDUSTRIALS · BUILDING PRODUCTS & EQUIPMENT · USA

Trane Technologies plc is an American Irish domiciled diversified industrial manufacturing company. It is headquartered near Dublin, Ireland.

Want to dig deeper into these stocks?